Form 8-K - Current report:
SEC Accession No. 0001193125-23-268167
Filing Date
2023-11-01
Accepted
2023-11-01 16:01:55
Documents
14
Period of Report
2023-10-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d514927d8k.htm   iXBRL 8-K 40914
2 EX-10.1 d514927dex101.htm EX-10.1 141297
3 EX-99.1 d514927dex991.htm EX-99.1 18565
  Complete submission text file 0001193125-23-268167.txt   373383

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA meip-20231031.xsd EX-101.SCH 2857
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE meip-20231031_lab.xml EX-101.LAB 17995
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE meip-20231031_pre.xml EX-101.PRE 11266
8 EXTRACTED XBRL INSTANCE DOCUMENT d514927d8k_htm.xml XML 3340
Mailing Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130
Business Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130 858-369-7100
MEI Pharma, Inc. (Filer) CIK: 0001262104 (see all company filings)

EIN.: 510407811 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-41827 | Film No.: 231368103
SIC: 2834 Pharmaceutical Preparations